Rokajax search

Wednesday, 18th May 2022



  • Home
  • Lopez Companies
    • Business and Finance
    • Calendar
    • Promos and Offers
    • Lopez Group Companies
  • HR Updates
    • HR Council
    • Business Excellence
    • Job Opportunities
  • Employee News
    • Message from Lopez
    • Meet the Executive
    • Meet the Team
    • Milestones
    • Spotlight
    • Advocacy
  • Corporate Sustainability
    • ABS-CBN Foundation
    • Sagip Kapamilya
    • OML Climate Change Center
    • Knowledge Channel
    • Lopez Museum
  • Lifestyle
    • Kapamilya Entertainment
    • Power Plant Mall Finds
    • ABS-CBN Publications
    • Food and Recipes
    • Lifelong Wellness
  • Blog
  • Lopez Values
    • 7 Lopez Values
    • The Credo
    • Web Comics
    • Special Feature

All about the vaxx

Twitter

All about the vaxxAll about the vaxxHeres a quick look at the main vaccine brands being used in Vac2Normal and in the Kapamilya Vaccination Program: AstraZeneca, Moderna and Novavax’s Covovax.

OXFORD ASTRAZENECA

Manufacturer/developer: AstraZeneca, University of Oxford (UK)

Countries with EUA: 99 countries including US, UK, Australia, Mexico, Argentina, India, Philippines

Philippine FDA EUA approval: January 28, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: Viral vector (nonreplicating)

Dose and frequency: 2 doses, 4-12 weeks apart

Vaccine efficacy (VE): 70.4% overall VE against symptomatic COVID-19, 14 days after the second dose

Common adverse events reported in Phase III clinical trials: Injection site pain and tenderness, fatigue, headache, feverishness, myalgia (muscle pain)

Serious adverse events reported in Phase III clinical trials: None reported

 

MODERNA

Manufacturer/developer: Moderna, National Institute of Allergy and Infectious Diseases (US)

Countries with EUA: 49 countries with EUA approval including US, UK, EU, Switzerland, Canada, Australia, Philippines

Philippine FDA EUA approval: May 5, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: mRNA

Dose and frequency: 2 doses, 28 days apart

Vaccine efficacy (VE): 94.1% overall VE against symptomatic COVID-19, occurring at least 14 days after the second dose; 100% VE against severe COVID-19

Common adverse events reported in Phase III clinical trials: Injection site pain, fatigue, headache myalgia (muscle pain), arthralgia (joint pain), chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site and erythema (skin redness/inflammation) at the injection site

Serious adverse events reported in Phase III clinical trials: Severe allergic reactions, including anaphylaxis

 

COVOVAX

Manufacturer/developer: Serum Institute of India, Novavax (US)

Countries with EUA: No EUA approvals yet

Philippine FDA EUA approval: --

Age group covered by FDA EUA approval: --

Technology platform: Protein subunit

Dose and frequency: 2 doses, 21 days apart

Vaccine efficacy (VE): Awaiting EUA application

Common adverse events reported in Phase III clinical trials: Awaiting EUA application

Serious adverse events reported in Phase III clinical trials: Awaiting EUA application (Source: doh.gov.ph)

 

More Articles from Lopezlink

ABS-CBN and its values-driven future

ABS-CBN and its values-driven future

11 mark milestones in 2017 Lopez Service Awards

11 mark milestones in 2017 Lopez Service Awards

Nationwide holidays for 2021

Erich triples the thrill in ‘The Blood Sisters’

Erich triples the thrill in ‘The Blood Sisters’

LAA 2017: 15 years of celebrating excellence

LAA 2017: 15 years of celebrating excellence

Lifetime Achievement Award for ABS-CBN CEO

Lifetime Achievement Award for ABS-CBN CEO

ABS-CBN forges ahead with 19 podcasts

ABS-CBN forges ahead with 19 podcasts

Darna 1st Filipino superhero to have a Funko collectible

Darna 1st Filipino superhero to have a Funko collectible

Angela Lopez: At your service

Angela Lopez: At your service

The pillow artists of Bantay Kalikasan

The pillow artists of Bantay Kalikasan

A Legacy of caring

A Legacy of caring

De Jesus makes ‘Modern Governance 100’ list

De Jesus makes ‘Modern Governance 100’ list

EDC, UP IB release ‘Wildlife Treasures’

EDC, UP IB release ‘Wildlife Treasures’

4th-gen Lopez launches new children’s book

4th-gen Lopez launches new children’s book

O Shopping: Changing the face of home shopping

O Shopping: Changing the face of home shopping

Subscribe to Lopezlink

Lopez Holdings Corp. All rights reserved



About Us | Copyright | Sitemap | Archive